Medpace Holdings, Inc. (MEDP) FY2026 Q2 P&L / Income Statement

Medpace Holdings, Inc. (MEDP) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenue, net (includes $4.7 million and $16.9 million with related parties for the three months ended June 30, 2026 and 2025, respectively, and $12.0 million and $30.7 million with related parties for the six months ended June 30, 2026 and 2025, respectively)

707,331,000 US dollars

Cost of revenue (calculated)

505,694,000 US dollars

Gross profit (calculated)

201,637,000 US dollars

Operating expenses (calculated)

54,813,000 US dollars

Income from operations

146,824,000 US dollars

Total other income (expense), net

4,839,000 US dollars

Income before income taxes

151,663,000 US dollars

Income tax provision

30,301,000 US dollars

Net income

121,362,000 US dollars

Metabolic

209,372,000 US dollars

Oncology

98,279,000 US dollars

Other

219,067,000 US dollars

Central Nervous System

59,982,000 US dollars

Cardiology

82,858,000 US dollars

Antiviral And Anti Infective

37,773,000 US dollars

Total direct costs

505,694,000 US dollars

Selling, general and administrative

48,103,000 US dollars

Depreciation

6,555,000 US dollars

Amortization

155,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.